Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia

BACKGROUND: Treatment‐free remission (TFR) has become the main target for chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKI) dose optimization is crucial in managing adverse events, and improving adherence in clinical practice. In persons achieving a deep molecular response (DMR), some...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yilin, Xu, Na, Yang, Yunfan, Liu, Zhenfang, Xue, Mengxing, Meng, Li, He, Qun, Chen, Chunyan, Zeng, Qingshu, Zhu, Huanling, Du, Xin, Zou, Jing, He, Wenjun, Guo, Jingming, Chen, Suning, Yuan, Guolin, Wu, Hui, Hong, Mei, Cheng, Fanjun, Liu, Bingcheng, Zhang, Yanli, Li, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501272/
https://www.ncbi.nlm.nih.gov/pubmed/37409506
http://dx.doi.org/10.1002/cam4.6296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501272/
https://www.ncbi.nlm.nih.gov/pubmed/37409506
http://dx.doi.org/10.1002/cam4.6296

Ejemplares similares